Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 39

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 39
---
 held by each of our existing stockholders, Sponsor, Iris’s independent directors, Cantor and the Liminatus Members will be different. (2) Assumes no additional stockholders exercise redemption rights. (3) Assumes that an additional 50%, or 87,238, shares of Iris Class A Common Stock are redeemed for cash. (4) Number of shares determined based on a price of $10.00 per share. Such price is subject to adjustment based on the five day volume-weighted average price prior to the filing of a resale registration statement covering such shares. Q: Will Iris obtain new financing in connection with the Business Combination? A: Yes. Concurrently with the execution of the Business Combination Agreement, and pursuant to the PIPE Equity Subscription Agreement, the PIPE Investor has committed to purchase 1,500,000 shares of ParentCo Common Stock at a purchase price per share of $10.00, for an aggregate purchase price of $15,000,000. The parties to the PIPE Equity Subscription Agreement entered into amendments to such agreement on August 14, 2023, March 9, 2024, July 23, 2024, August 16, 2024, October 31, 2024 and December 26, 2024 to, among other things, extend the date the PIPE Investor can terminate such agreement.

xii

TABLE OF CONTENTS

For a summary of the material terms of the PIPE Equity Subscription Agreement, see the section entitled “Proposal No. 1 — The Business Combination Proposal — Additional Agreements Executed at the Signing of the Business Combination Agreement ” for more information.

**Q:

What conditions must be satisfied to complete the Transactions?

A:

There are a number of closing conditions in the Business Combination Agreement, including that our stockholders have approved the Transactions and adopted the Business Combination Agreement. For a summary of the conditions that must be satisfied or waived prior to completion of the Transactions, see the section entitled “ Proposal No. 1 — The Business Combination Proposal .”

Q:

Why is Iris proposing the Incentive Plan Proposal?

A:

The purpose of the Incentive Plan is to provide eligible employees, directors and consultants of ParentCo the opportunity to receive stock-based incentive awards in order to encourage such persons to contribute materially to the growth of ParentCo and align their economic interests with those of its stockholders.

Q:

What happens if I sell my shares of Iris common stock before the Special Meeting?

A:

The record date for the Special Meeting is ,